Del Mar Pharmaceuticals to Present at 5th Annual Biotech Showcase

VANCOUVER, BRITISH COLUMBIA – (January 4, 2013) DelMar Pharma, a clinical and commercial stage drug development company with a focus on the treatment of cancer, today announced that Chief Executive Officer Jeffrey Bacha will present recent updates to potential investors during Biotech Showcase 2013. The annual conference is scheduled for January 7th-9th at the Parc 55 Wyndham in San Francisco, USA.

Mr. Bacha is scheduled to give a corporate presentation at 10:30AM PST on Wednesday, January 9th. In addition, Bacha, along with DelMar Pharma’s Chief Scientific Officer, Dr. Dennis Brown will be available throughout the event for one-on-one meetings with investors by appointment only. To schedule a meeting, registered attendees can submit a meeting request through the conference website (www.ebdgroup.com/bts).

About DelMar Pharma

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company’s lead asset, VAL-083, benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved as a cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

For further information, please visit www.delmarpharma.com or contact Jeffrey A. Bacha, President & CEO +1 (604) 629-5989

Released January 4, 2013